RxDoctor Payments Data

Christina Dolack, DO

Internal Medicine · Asheville, NCNPI 1154424661

Payments from drug & device makers

$834in general payments, 2019–2025

Across 14 payments — averaging $59.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$277
  • Sumitomo Pharma America, Inc.$125
  • Acadia Pharmaceuticals Inc$122
  • Otsuka America Pharmaceutical, Inc.$120
  • Teva Pharmaceuticals USA, Inc.$114
  • Sunovion Pharmaceuticals Inc.$41
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$834100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$834 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$176,777
Medicare patients
248
Services billed
1,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban739$230,407
TrulicityDulaglutide204$129,616
BiktarvyBictegrav/Emtricit/Tenofov Ala40$119,711
XifaxanRifaximin60$100,289
GlatopaGlatiramer Acetate48$60,473
JanuviaSitagliptin Phosphate152$50,508
Austedo XrDeutetrabenazine18$47,925
XareltoRivaroxaban157$45,215
IngrezzaValbenazine Tosylate11$40,770
JardianceEmpagliflozin86$29,165
Spiriva RespimatTiotropium Bromide46$25,365
Incruse ElliptaUmeclidinium Bromide52$19,263
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$17,483
TradjentaLinagliptin39$17,210
LinzessLinaclotide41$16,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$20$50,508152 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$114$47,92518 claims
Neurocrine Biosciences, Inc.Ingrezza$277$40,77011 claims
AstraZenecaSymbicort, Lokelma$15$15,60056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →